Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO
- Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer
- Full results will be presented in an oral abstract session at the?ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO)
ITT (TPS=1%) N=135 | PD-L1-high (TPS=50%) N=58 | PD-L1-low (TPS1-49%) N=77 | ||||
Arms | tiragolumab + Tecentriq (n=67) | placebo + Tecentriq (n=68) | tiragolumab + Tecentriq (n=29) | placebo + Tecentriq (n=29) | tiragolumab+ Tecentriq (n=38) | placebo + Tecentriq (n=39) |
ORR, % (95% CI) | 31.3 (19.5, 43.2) | 16.2 (6.7, 25.7) | 55.2 (35.3, 75.0) | 17.2 (1.8, 32.7) | 13.2 (1.15, 25.2) | 15.4 (2.8, 28.0) |
Odds ratio (95% CI) | 2.57 (1.07,6.14)* | 5.91 (1.76,19.81)? | 0.83 (0.23, 3.00)? | |||
Median PFS (95% CI) | 5.4 (4.2, NE) | 3.6 (2.7, 4.4) | NE (5.4, NE) | 3.9 (2.1, 4.7) | 4.1 (1.6, 5.6) | 3.6 (1.5, 5.0) |
HR (95% CI) | 0.57 (0.37,0.90)* | 0.33 (0.15, 0.72)? | 0.85 (0.49, 1.48)? |
tiragolumab + Tecentriq n=67 | placebo + Tecentriq n= 68 | |
All Grade 3-5 AEs | 41.8% | 44.1% |
Treatment- related AEs (TRAEs) | 80.6% | 72% |
Grade? =3 TRAEs | 14.9% | 19.1% |
AEs leading to treatment withdrawal | 7.5% | 10.3% |
Attachment